Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Oct 16, 2025 · Filed Oct 16, 2025
The boss of Cytokinetics sold $300K of Cytokinetics shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$300,150
Shares × reported transaction price
70 days after results of Aug 7, 2025, 20 days before results of Nov 5, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.0% | +1.9% | −3.0% |
| 30 days | +14.6% | +0.2% | +14.4% |
| 90 days | +8.6% | +4.2% | +4.4% |
| 180 days | +11.9% | +5.3% | +6.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Director sold ~$337K of Cytokinetics
Automatic saleDerivative exercise or conversion — not an open-market buy.